Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $104.14.

LNTH has been the subject of a number of research reports. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. Truist Financial reissued a "buy" rating and set a $82.00 price target (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Saturday, January 13th. B. Riley reduced their target price on shares of Lantheus from $113.00 to $95.00 and set a "buy" rating on the stock in a report on Wednesday, January 10th. Finally, William Blair cut shares of Lantheus from an "outperform" rating to a "market perform" rating in a research report on Monday, December 18th.

Lantheus Trading Down 1.2 %

LNTH traded down $0.71 on Friday, hitting $60.79. The company had a trading volume of 654,657 shares, compared to its average volume of 794,420. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. The firm has a market cap of $4.17 billion, a P/E ratio of 13.10 and a beta of 0.53. The company's fifty day moving average price is $60.13 and its 200 day moving average price is $63.13. Lantheus has a 1 year low of $50.20 and a 1 year high of $100.85.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. As a group, equities analysts expect that Lantheus will post 5.72 earnings per share for the current year.

Insider Transactions at Lantheus

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm's stock in a transaction on Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. In the last three months, insiders sold 94,545 shares of company stock valued at $6,168,153. Insiders own 1.50% of the company's stock.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. City State Bank raised its position in Lantheus by 44.6% in the 1st quarter. City State Bank now owns 1,945 shares of the medical equipment provider's stock valued at $121,000 after purchasing an additional 600 shares during the last quarter. Silverberg Bernstein Capital Management LLC increased its stake in Lantheus by 1.8% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 22,743 shares of the medical equipment provider's stock valued at $1,416,000 after purchasing an additional 400 shares during the period. Private Capital Management LLC raised its holdings in shares of Lantheus by 27.9% in the fourth quarter. Private Capital Management LLC now owns 556,771 shares of the medical equipment provider's stock valued at $34,520,000 after buying an additional 121,290 shares during the last quarter. Clearview Wealth Advisors LLC acquired a new stake in shares of Lantheus during the first quarter worth about $342,000. Finally, Juncture Wealth Strategies LLC purchased a new position in shares of Lantheus during the first quarter worth about $382,000. Institutional investors and hedge funds own 99.06% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.